Trial Profile
A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Napabucasin (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Ibrutinib; Imatinib
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Boston Biomedical; Sumitomo Pharma Oncology
- 25 Mar 2019 Status changed from active, no longer recruiting to completed.
- 30 Mar 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
- 20 Dec 2016 Status changed from recruiting to active, no longer recruiting.